The drugmaker released its fourth quarter and 2021 financial results Feb. 1.
Gilead reported $1.4 billion in sales for Veklury in the fourth quarter of 2021, a decrease of about 30 percent from the same quarter in 2020. However, full-year revenue for Veklury hit $5.6 billion in 2021, a 98 percent jump from 2020 revenue.
Gilead said Veklury sales closely align with COVID-19 hospitalization trends in the U.S. The drugmaker said it expects hospitalization rates to fall in 2022 but is still projecting $2 billion in Veklury sales this year.
The FDA approved Veklury for use in all hospitalized COVID-19 patients 12 and older in October 2020. On Jan. 21, the agency authorized use of the drug in nonhospitalized patients with mild to moderate COVID-19 who have a high risk of their cases becoming severe.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
